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Abstract
Purpose—Controversy exists regarding adjuvant oxaliplatin treatment among older stage II and
III colorectal cancer (CRC) patients. We sought to identify patient/tumor, physician, hospital, and
geographic factors associated with oxaliplatin use among older patients.
Methods—Individuals diagnosed at age>65 with stage II/III CRC from 2004–2007 undergoing
surgical resection and receiving adjuvant chemotherapy were identified using the Surveillance,
Epidemiology and End Results program (SEER)-Medicare, a database including patient/tumor and
hospital characteristics. Physician information was obtained from the American Medical
Association. We used Poisson regression to identify independent predictors of oxaliplatin receipt.
The discriminatory ability of each category of characteristics to predict oxaliplatin receipt was
assessed by comparing the area under the receiver operating curve (AUC) from logistic regression
models.
Results—We identified 4,388 individuals who underwent surgical resection at 773 hospitals and
received chemotherapy from 1,517 physicians. Adjuvant oxaliplatin use was higher among stage
III (colon=56%, rectum=51%) compared to stage II patients (colon=37%, rectum=35%). Overall,
patients who were older, diagnosed before 2006, separated, divorced or widowed, living in a
higher poverty census tract or in the East or Midwest, or with higher levels of comorbidity were
less likely to receive oxaliplatin. Patient factors and calendar year accounted for most of the
variation in oxaliplatin receipt (AUC=75.8%).
Conclusion—Adjuvant oxaliplatin use increased rapidly from 2004–2007 despite uncertainties
regarding its effectiveness in older patients. Physician and hospital characteristics had little
influence on adjuvant oxaliplatin receipt among older patients.
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In 2011, an estimated 141,210 patients were diagnosed with colorectal cancer (CRC) in the
United States (US), with 49,380 deaths.1 Healthcare spending for CRC was estimated at
$14.1 billion in 2010.2, 3 As the median age at CRC diagnosis is 69 years, older patients
account for a substantial portion of the overall CRC disease burden in the US.4
Adjuvant chemotherapy after surgical resection improves overall survival among older stage
III colon cancer patients. Three adjuvant chemotherapies are available and include 5-
fluorouracil (FU), capecitabine, or the combination of 5-FU or capecitabine with oxaliplatin;
no other agents have been shown to improve outcomes.5–8 Adjuvant chemotherapy with 5-
FU compared to surgery alone reduces the risk of death by 24% among older stage III colon
cancer patients.9 Randomized controlled trials (RCTs) demonstrated that adding adjuvant
oxaliplatin to 5-FU leads to an incremental 4.2% reduction in death among patients with
stage III colon cancer.10–13 However, individuals enrolled in these RCTs had a median age
at diagnosis of 60–63 years, and only 17% were ≥70 years,14 limiting the generalizability of
these findings to older patients. Recent studies15–21 have shown that the addition of adjuvant
oxaliplatin to 5-FU or capecitabine results in minimal, if any incremental survival benefit for
older stage III colon cancer patients and average risk stage II colon cancer patients. Based
upon these findings, the National Comprehensive Cancer Network (NCCN) guidelines now
state that there is no demonstrated benefit to the addition of adjuvant oxaliplatin to 5-FU in
average-risk stage II colon cancer or in patients >70 years.22 The role of adjuvant oxaliplatin
in rectal cancer is not yet defined.
In light of the growing concerns regarding the incremental benefits of oxaliplatin in addition
to 5-FU in these subgroups and the lack of RCT evidence regarding its role in rectal cancer,
we sought to examine the dissemination of adjuvant oxaliplatin among older patients and
factors influencing its use in routine clinical practice.”
METHODS
Data sources
The SEER-Medicare database is a linkage of two large population-based data sources
providing detailed clinical and healthcare utilization information on Medicare beneficiaries
diagnosed with cancer.23 The SEER registries collect demographic, clinical and tumor
characteristics, vital status, and cause of death for all incident cancers reported for
individuals residing within one of the registry areas, covering approximately 28% of the
US.24 Patients in SEER are linked to their Medicare Part A and B claims.25 Nearly all
Medicare beneficiaries are eligible for Part A and almost 93% opt to enroll in the Part B.26
The SEER-Medicare Hospital file reports descriptive information for hospitals that are part
of the SEER-Medicare database,27 including whether hospitals were NCI-designated cancer
centers or participated in cooperative groups for clinical trials. Medicare claims were linked
to the Hospital file using a unique number. The AMA Physician Masterfile data contain
information on the characteristics of >1 million physicians in the US which are linked to
Medicare claims by each physician’s Unique Physician Identification Numbers
(UPINs).28–30
Study Cohort
We identified all patients in the SEER data diagnosed at age >65 with their first primary
stage II or III cancer of the colon or rectum.31 Exclusions included: diagnoses at autopsy or
death; a missing month of diagnosis; those without continuous Medicare Part A and B fee-
for-service enrollment for the 12-months before and 8-months after diagnosis (as healthcare
utilization and treatment information would not be complete for all patients).
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To identify characteristics of the hospital where cancer surgery was performed, we restricted
this cohort to individuals with a surgical claim (i.e., colectomy or proctectomy) in the 6-
months following diagnosis. If a patient had surgical claims from multiple hospitals, the first
hospital was retained for analysis. We linked the cohort to the SEER-Medicare Hospital file
by the provider number and year of diagnosis for each patient. Hospitals that did not match
were excluded.
To examine characteristics of physicians providing chemotherapy, eligible patients had to
have at least one claim for a specific chemotherapeutic agent during the initial chemotherapy
treatment period (described below). The physician with the most chemotherapy-related
claims during the initial chemotherapy treatment period was considered the treating
physician.32 UPINs that did not match to the AMA Physician Masterfile were excluded.
Measurement of adjuvant oxaliplatin
We categorized patients as receiving adjuvant chemotherapy with oxaliplatin or without
oxaliplatin using the algorithm in Figure 1. Because adjuvant chemoradiotherapy for rectal
cancer may be delivered pre- or post-operatively, a different exposure window was required
for patients receiving post-operative adjuvant radiotherapy to distinguish between
radiosensitizing chemotherapy and systemic adjuvant chemotherapy. We defined adjuvant
chemotherapy using a 120-day window to avoid misclassifying chemotherapy for recurrent
cancer as adjuvant therapy. Patients were divided into an oxaliplatin group, those having ≥1
claim for oxaliplatin within 60 days from the first chemotherapy claim, and a non-
oxaliplatin group, those without any oxaliplatin claims within 60 days from the first
chemotherapy. The validity of Medicare claims to identify chemotherapy administration and
oxaliplatin has been previously reported to be high.33, 34
Patient characteristics
Characteristics including year of diagnosis, sex, age at diagnosis (66–69, 70–74, 75–79, 80–
84, or 85+), race/ethnicity (White Non-Hispanic, Black Non-Hispanic, Other Non-Hispanic,
Hispanic, or Unknown), marital status (married, single, other (divorced, separated,
widowed), or unknown), and region of residence (Northeast, South, Midwest, or West) came
from SEER. County-level metropolitan area was defined as metropolitan or non-
metropolitan. Census tract level information about the percentage of residents living below
the federal poverty level served as an aggregate measure of socioeconomic status and was
categorized into quartiles: ≤4%, 4.01–≤8%, 8.01–≤15%, and >15, as the census tract poverty
variable may be the best proxy measure of SES for elderly Medicare beneficiaries.35, 36
Each patient’s pre-existing health conditions in the 365 days pre-diagnosis were measured
using the Klabunde adaptation of the Charlson Comorbidity Index (CCI).37
Hospital and physician characteristics
Hospital characteristics included NCI center designation (none, clinical, or comprehensive),
NCI cooperative membership group count (0 or ≥1), teaching hospital status (yes/no), type
of hospital (non-profit, private, or government), and total bed size, measured in quartiles
(<204, 204–343, 344–487, or 488+). Physician characteristics included medical degree
(Medical Doctor (MD) or Doctor of Osteopathy (DO)), whether the physician was trained in
the US (yes/no), year of medical school graduation (<1981 or ≥1981), primary specialty
(oncology, hematology/oncology, hematology, internal medicine, or other), and sex.
Statistical analysis
We estimated the proportion of patients receiving adjuvant oxaliplatin by year, cancer site,
and stage. Bivariable prevalence ratios (PRs) for the receipt of oxaliplatin were calculated
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for each multilevel characteristic. Patient observations were clustered within hospitals and
physicians in a non-nested manner. Our analysis accounted for this correlation and produced
estimates of marginal (population-averaged) associations.38 We estimated adjusted PRs
(aPRs) for all variables using multivariable Poisson models with a log link and generalized
estimating equations with an independent working correlation matrix. Stratified analyses for
colon and rectal cancer were performed. Finally, we assessed the discriminatory ability of a
variety of logistic regression models to determine adjuvant oxaliplatin receipt by comparing
the area under the receiver operating curve (AUC). Models included combinations of
calendar year and patient/tumor, physician, hospital, and geographic characteristics. All
analyses were conducted using the SAS Version 9.2 (SAS Institute, Inc., Cary, NC).
RESULTS
We identified 4,388 patients diagnosed with stage II or III CRC who received chemotherapy
and met all eligibility criteria for inclusion (Figure 2). The study population was primarily
over the age of 70 at diagnosis (73%), White Non-Hispanic (81%), married (61%), living in
a metropolitan area (84%), and free from comorbidities (68%). Most tumors were located in
the colon (85%) and diagnosed at stage III (74%) (Table 1).
The majority of the 1,517 physicians were male (81%), MDs (97%), US-trained (67%),
medical school graduates ≥1981 (56%) with a primary specialty of oncology or hematology/
oncology (76%) (Table 2). Three percent of the 773 hospitals had a NCI clinical or
comprehensive cancer center designation and 48% had at least one cooperative group
membership. Almost 40% were teaching hospitals and 62% were non-profit entities.
The prevalence of adjuvant oxaliplatin treatment over the 4-year study period was 52% and
46% for patients diagnosed with colon and rectal cancer, respectively. There was a steady
increase in the prevalence of adjuvant oxaliplatin use over time which was similar for all site
and stage subgroups (Figure 3). By 2007, 60% and 73% of stage II and III colon and 52%
and 68% of stage II and III rectal cancer patients received oxaliplatin, respectively.
Patients diagnosed in earlier years were less likely to receive adjuvant oxaliplatin than those
diagnosed in 2007 (e.g., 2004: aPR=0.42, 95% CI: (0.37, 0.47), Figure 4). Patients with
colon vs. rectal cancer were more likely to receive oxaliplatin (aPR=1.15, 95% CI: (1.05,
1.26)), whereas those with stage II vs. III disease were less likely (aPR= 0.65, 95% CI:
(0.60, 0.71)). Increasing age was associated with a gradual monotonic decrease in the
likelihood of oxaliplatin receipt (e.g., 85+ vs. 66–69: aPR =0.22, 95% CI: (0.14, 0.34)) and
patients with increased comorbidities were less likely to receive oxaliplatin compared to
those with no comorbidity (e.g., Charlson Score of 1 vs. 0: aPR= 0.92, 95% CI: (0.87, 0.98).
Additionally, patients who were separated, divorced or widowed (vs. married), living in the
East or Midwest (vs. West), residing in a non-metropolitan area (vs. metropolitan area) or in
a census tract with a higher proportion of individuals living under the poverty level were less
likely to receive oxaliplatin. No physician- or hospital-level variables were strongly
associated with adjuvant oxaliplatin receipt in the overall analysis. Results from the cancer
site-stratified analyses were similar, although less precise for rectal cancer due the smaller
number of patients (data not shown). Two exceptions were that among rectal cancer patients,
surgical treatment at an NCI comprehensive cancer center was associated with increased
adjuvant oxaliplatin use (aPR=1.48, 95% CI: 1.15, 1.90), while Hispanic ethnicity was
associated with decreased use (aPR=0.52, 0.32, 0.86). Among stage II colon cancer patients,
more patients with T4 tumors (40%) received oxaliplatin compared to those with T3 tumors
(36%).
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The category headings in Figure 4 denote the AUC for components of the logistic regression
model (calendar year, patient/tumor, physician, hospital, and geographic). The AUC reports
the ability of each model to accurately distinguish between those patients who received
adjuvant oxaliplatin and those who did not. When calendar year was included alone, the
model had fair ability to discriminate oxaliplatin users (AUC=68%). The addition of patient/
tumor factors enhanced the model’s discriminatory ability (AUC=75.8 %). However, when
physician, hospital, and geographic factors were added separately to calendar year, the AUC
only increased to 68.9%, 68.9%, and 69.1% respectively. The full model AUC was 76.6%;
therefore, among patients who received chemotherapy, physician and hospital characteristics
contributed very little to the determination of oxaliplatin receipt.
DISCUSSION
This population-based analysis demonstrates substantial increases in oxaliplatin use among
older stage II and III CRC patients who received chemotherapy from 2004–2007. By 2007,
the prevalence of oxaliplatin treatment was 60% and 73% among stage II and III colon
cancer patients and 52% and 68% among stage II and III rectal cancer patients, respectively.
Patient- and tumor-level characteristics, together with calendar year, accounted for most of
the discriminatory power in determining oxaliplatin use in older CRC patients, while
physician and hospital characteristics contributed little.
Patients treated by providers within the Community Clinical Oncology Program (CCOP), a
network connecting NCI cooperative groups to community physicians treating cancer
patients, were recently found to be more likely than those who did not to receive adjuvant
oxaliplatin.39 CCOP data was not available for our analysis; however, when restricted to
stage III colon cancer patients, we did not find an association between hospital cooperative
group participation and adjuvant oxaliplatin use (aPR=0.98, 95% CI: 0.91, 1.05). This
discrepancy may reflect that our study examined a slightly later time period, potentially
weakening the impact of cooperative group membership on oxaliplatin diffusion. By 2007,
73% of all older stage III colon cancer patients in our study received adjuvant chemotherapy
with oxaliplatin, suggesting that its adoption in routine practice was rapid and widespread
across all physicians. However, our finding that rectal cancer patients undergoing surgery at
an NCI comprehensive cancer centers were more likely to receive adjuvant oxaliplatin
compared with similar patients at hospitals without an NCI designation may be due to the
unique timing and coordination of surgery, radiation, and chemotherapy required for rectal
cancer treatment. The sex and race/ethnicity of patients were not predictive of adjuvant
oxaliplatin receipt, which may reflect the uniform insurance setting of our study limiting
variations in access to care.
Among patient subgroups where RCT evidence is entirely lacking (i.e., stage II and III rectal
cancer) or has shown no benefit (i.e., stage II colon cancer),11 we found widespread
adjuvant oxaliplatin use by 2007 in older CRC patients. Well over half of all stage II colon
and stage II and III rectal cancer patients undergoing adjuvant chemotherapy received
oxaliplatin as part of their adjuvant chemotherapy. Rectal cancer patients have not been
included in RCTs examining adjuvant oxaliplatin and as such, there is no phase III evidence
supporting its use. It is possible that higher local and systemic recurrence rates lead
physicians and older patients to choose adjuvant oxaliplatin treatment;40, 41 however, the
added toxicity of (neo)adjuvant radiotherapy makes tolerance of adjuvant chemotherapy
more challenging. Whether this practice is appropriate will hopefully be answered by
ongoing trials examining the role of oxaliplatin in adjuvant chemotherapy of rectal cancer
(PETACC 6 and German Rectal Cancer Study Group CAO/ ARO/AIO-04). However, these
trials are unlikely to include adequate numbers of older rectal cancer patients for sub-
analysis, and therefore some uncertainty will remain.
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Even in colon cancer, the evidence to support the addition of adjuvant oxaliplatin to 5-FU in
older patients is weak. An initial pooled analysis of four RCTs demonstrated that the
efficacy of adding oxaliplatin to 5-FU was similar in older and younger patients with stage
III and metastatic CRC.14 However, three recent RCT analyses relying on subgroup or
pooled data have reported conflicting results regarding the efficacy of adjuvant oxaliplatin in
older patients.19, 20, 42 Two analyses of multiple observational databases found that the
addition of adjuvant oxaliplatin treatment may benefit those younger than 75 years old,17 but
for those ≥80 any benefit is likely modest.18 Therefore, as controversy remains regarding
adjuvant oxaliplatin in older stage III colon cancer patients, any potential benefits must be
carefully considered alongside patient preferences and the cost and risk of adverse events.
Our study has multiple strengths. The cohort included a large sample derived from
population-based cancer registries linked to longitudinal Medicare claims. These data were
augmented by information in the AMA Masterfile and SEER-Medicare Hospital file. The
aggregation of data resulted in a rich data source to examine the influence of multilevel
characteristics on the receipt of oxaliplatin. Our analysis reflects patterns of chemotherapy
use in the community setting.
However, our study is limited by the constraints of the data sources. SEER-Medicare
contains information on many patient and tumor characteristics that may be associated with
treatment patterns, but unobserved factors such as patient preferences, financial
considerations, or functional status may also influence treatment decisions. Further linkage
efforts to data sources including electronic medical records or patient surveys may improve
measurement of these factors for future research. Because clinical stage was not available in
the SEER data, we relied upon pathological staging and as a result may have selected
neoadjuvantly-treated rectal cancer patients with a poorer prognosis. Our analysis did not
examine within-physician variation in prescribing using a random effects framework, which
may further illuminate patterns of physician preference regarding the use of oxaliplatin.
Lastly, a number of exclusions were made in the creation of our study population and thus
the findings from our analysis may not be generalizable to individuals <66 years or managed
care enrollees.
In conclusion, adjuvant oxaliplatin was increasingly used to treat stage II and III CRC
patients following its approval in 2004 and its use was influenced strongly by patient, as
opposed to physician or hospital, characteristics. By 2007, 70% of all chemotherapy-treated
stage II and III CRC patients received adjuvant oxaliplatin, despite no evidence to support
its use in rectal cancer, and mounting evidence against its use in stage II and older stage III
colon cancer patients. The widespread dissemination of oxaliplatin into the older population
highlights the critical importance of studying the benefits of anticancer therapies in older
patient populations. Future studies should focus on the comparative effectiveness and safety
of adjuvant chemotherapy with oxaliplatin in older stage II and III rectal cancer patients, as
utilization within these patient groups were substantial and the evidence for benefit and
harm are unknown.
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Figure 1. Administrative algorithms used to define adjuvant chemotherapy treatment for stage
II and III colorectal cancer patients
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Figure 2. Study population flow chart
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Figure 3. Prevalence of adjuvant oxaliplatin use by cancer site and stage among older colorectal
cancer patients who received chemotherapy treatment from 2004–2007
The annual prevalence among stage II and III colon cancer patients is represented by the
black dashed and solid line, respectively, and among stage II and III rectal cancer patients by
the grey dashed and solid line, respectively. Less than 3% (n=114) of patients received
adjuvant irinotecan during the study period.
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Figure 4. Forest plot summarizing the multivariable adjusted prevalence ratio estimates for the
associations between multilevel characteristics and adjuvant oxaliplatin receipt among older
stage II and III CRC patients treated with chemotherapy
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